A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.

Messori, A; Fadda, V; Trippoli, S

Messori, A; Fadda, V; Trippoli, S.

Affiliation

Messori A; Laboratorio di Farmacoeconomia, c/o University of Florence, Via Guimaraes 5-7, 59100 Prato, Italy. messoriandrea@interfree.it

J Chemother ; 23(2): 67-70, 2011 Apr.

Article in En | MEDLINE | ID: mdl-21571620

Subject(s)

Antineoplastic Agents/economics; Antineoplastic Agents/therapeutic use; Neoplasms/drug therapy; Off-Label Use/economics; Reimbursement Mechanisms/economics; Cost-Benefit Analysis/methods; Cost-Benefit Analysis/statistics & numerical data; Disease-Free Survival; Humans; Italy

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Reimbursement Mechanisms / Off-Label Use / Neoplasms / Antineoplastic Agents Type of study: Health_economic_evaluation Limits: Humans Country/Region as subject: Europa Language: En Journal: J Chemother Journal subject: ANTINEOPLASICOS / TERAPIA POR MEDICAMENTOS Year: 2011 Document type: Article Affiliation country: Italy

Search on Google

Add to My VHL

XML

PubMed Links